Selective targeting phosphodiesterase-5 (PDE5): clinical progress, design strategies, and emerging prospects.
Level 5 - mechanism / opinion, no new human data
Narrative review of medicinal chemistry design strategies and clinical applications
PubMed 42390922 · doi:10.1080/14756366.2026.2687714
What was done
This review evaluates the clinical progress, rational drug design strategies, structural advantages, and limitations of phosphodiesterase-5 (PDE5) inhibitors possessing diverse chemical scaffolds.
What was found
The abstract reports no quantitative findings or numerical comparative data. It highlights that approved PDE5 inhibitors (such as sildenafil, tadalafil, and vardenafil) are effective for pulmonary arterial hypertension and erectile dysfunction but produce adverse effects, including headaches and visual disturbances, attributed to low subtype selectivity.
Why it matters
Understanding the structural and chemical limitations of existing drugs provides a framework for developing next-generation PDE5 inhibitors with enhanced subtype selectivity and fewer adverse effects.
Limits
The abstract contains no primary experimental or clinical trial data, no quantitative selectivity ratios, and no details regarding systematic literature search criteria.
Cited by
- contradicts Tadalafil was developed first as a prostate health drug before it was found to treat erectile dysfunction at higher doses.